Health Canada Grants Authorization for “LEQEMBI(R)” (lecanemab) for the Treatment of Early Alzheimer’s Disease
Health Canada Grants Authorization for “LEQEMBI(R)” (lecanemab) for the Treatment of Early Alzheimer's Disease In Canada, lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment or mild dementia due to Alzheimer's disease (early AD) who are apolipoprotein E ε4 (ApoE ε4*) non-carriers or heterozygotes and who have […]